Table 2.
Primary and secondary outcomes: mixed effects models
| ITT analyses | Sensitivity analyses | |||||
|---|---|---|---|---|---|---|
| Time | Group | Time * group | Time | Group | Time * group | |
| F (p) | F (p) | F (p) | F (p) | F (p) | F (p) | |
| GAD‐7 | 30.94 (<0.001) | 4.26 (0.04) | 4.17 (0.01) | 30.75 (<0.001) | 7.23 (0.01) | 4.93 (0.002) |
| PHQ‐9 | 23.65 (<0.001) | 2.06 (0.15) | 2.74 (0.04) | 23.16 (<0.001) | 8.50 (0.004) | 2.92 (0.03) |
| SATMED‐Q | 33.14 (<0.001) | 1.07 (0.30) | 0.11 (0.95) | 31.95(<0.001) | 6.55 (0.01) | 0.23 (0.88) |
| SDS | 33.01 (<0.001) | 1.02 (0.31) | 6.25 (<0.001) | 33.13 (<0.001) | 3.41 (0.07) | 7.33(<0.001) |
Abbreviations: F, F‐statistic; GAD‐7, Generalized Anxiety Disorder 7; ITT, intention‐to‐treat; PHQ‐9, Patient Health Questionnaire 9; SATMED‐Q, Treatment Satisfaction with Medicines Questionnaire; SDS, Sheehan Disability Scale.